FDA changes rule for heparin labels; Moderna says its process would underprice biopharmaceutical manufacturing;

 @EricPFierce: Happy Holidays from FDA. It extends to Dec. 18 the deadline to register API and generic drug manufacturing plants. More | Follow @EricPFierce

> The FDA is eliminating the need of healthcare providers to do dilution calculations on heparin products by requiring manufacturers to label "Heparin Lock Flush Solution, USP and Heparin Sodium Injection, USP to clearly state the strength of the entire container of the medication followed by how much of the medication is in 1 milliliter (mL)." Announcement

> A new bill has been introduced into the House of Representatives that would require compounding pharmacies to register with the FDA, and permit the agency to set production levels that would require agency inspection, although the legislation is unlikely to be taken up this year. Story

> China's Biostar Pharmaceuticals ($BSPM) has a new one-year, $8 million contract with China's Xijing Military Hospital to manufacture 16 drugs. Item

> German manufacturer Sanner, which makes plastic packaging and components, is modernizing its plant in Bensheim. Item

> Boehringer Ingelheim Biopharmaceuticals has a new deal to manufacture products for Apexigen, an emerging U.S. company working on therapeutic monoclonal antibodies. Story

And Finally... Moderna Therapeutics says its new process for treating patients with therapeutic proteins made in their own bodies could replace the need for biomanufacturing plants. Story

Suggested Articles

Neopharma, which has been buying and building plants for several years, is buying a sterile injectables plant and assets in Japan from India’s Lupin. 

Already knocked by the FDA four times this year, Dr. Reddy’s now has a fifth Form 483 to dwell on. This time it’s at a plant with a history of faults.

In a warning letter, the FDA details how a Chinese OTC drugmaker handed over documents faked just for the agency's inspection—and admitted it.